Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?

被引:4
|
作者
Wiesik-Szewczyk, Ewa [1 ]
Kucharczyk, Aleksandra [1 ]
Swierkocka, Katarzyna [2 ]
Rutkowska, Elzbieta [3 ]
Jahnz-Rozyk, Karina [1 ]
机构
[1] Mil Inst Med Warsaw, Dept Internal Med Pulmonol Allergy & Clin Immunol, Cent Clin Hosp, Minist Natl Def, Warsaw, Poland
[2] Natl Inst Geriatr Rheumatol & Rehabil, Dept Connect Tissue Dis, Warsaw, Poland
[3] Mil Inst Med Warsaw, Hematol & Flow Cytometry Lab, Dept Internal Med & Hematol, Cent Clin Hosp,Minist Natl Def, Warsaw, Poland
关键词
Biologics; CVID; DMARDS; Infections; Psoriatic arthritis; COMMON VARIABLE IMMUNODEFICIENCY; RHEUMATOID-ARTHRITIS; THERAPY; DISORDERS;
D O I
10.1007/s10067-017-3670-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 54-year-old man with confirmed psoriatic arthritis, treated with conventional and biologic disease-modifying anti-rheumatic drugs, suffered from severe, recurrent respiratory tract infections. He was found to have hypogammaglobulinemia. Further investigations confirmed the diagnosis of common variable immunodeficiency. Introduction of immunoglobulin G replacement therapy allowed for safe and effective treatment of psoriatic arthritis with etanercept and methotrexate. Patients with a history of recurrent infections on disease-modifying anti-rheumatic drugs and hypogammaglobulinemia should be assessed for primary antibody immunodeficiencies, even in adulthood.
引用
收藏
页码:1677 / 1681
页数:5
相关论文
共 50 条
  • [31] The use of conventional disease-modifying anti-rheumatic drugs in established RA
    Jurgens, M. S.
    Jacobs, J. W. G.
    Bijlsma, J. W. J.
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2011, 25 (04): : 523 - 533
  • [32] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [33] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [34] INFECTIOUS COMPLICATIONS AS A REASON FOR THE CANCELLATION OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Aronova, E.
    Gridneva, G.
    Kudryavtceva, A.
    Dydykina, I.
    Lukina, G.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S250 - S250
  • [35] Onset of myasthenia gravis in a patient affected by rheumatoid arthritis never treated with disease-modifying anti-rheumatic drugs
    Coaccioli, S
    Ponteggia, F
    Di Cato, L
    Allegra, A
    Puxeddu, A
    [J]. PANMINERVA MEDICA, 1999, 41 (02) : 135 - 137
  • [36] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    [J]. Clinical Rheumatology, 2020, 39 : 207 - 216
  • [37] Ovarian Reserve in Children with Juvenile Idiopathic Arthritis Using Biologic Disease-Modifying Anti-Rheumatic Drugs
    Ozer, Yavuz
    Yildiz, Mehmet
    Turan, Hande
    Tarcin, Gurkan
    Aydin, Dilek Bingol
    Gunalp, Aybuke
    Haslak, Fatih
    Konte, Elif Kilic
    Aslan, Esma
    Koker, Oya
    Bayramoglu, Elvan
    Sahin, Sezgin
    Adrovic, Amra
    Barut, Kenan
    Kasapcopur, Ozgur
    Evliyaoglu, Olcay
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 400 - 400
  • [38] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Roy Fleischmann
    [J]. Clinical Rheumatology, 2021, 40 : 4369 - 4372
  • [39] Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs
    Ozer, Yavuz
    Yildiz, Mehmet
    Turan, Hande
    Tarcin, Gurkan
    Aydin, Dilek Bingol
    Gunalp, Aybuke
    Haslak, Fatih
    Konte, Elif Kilic
    Aslan, Esma
    Koker, Oya
    Bayramoglu, Elvan
    Sahin, Sezgin
    Adrovic, Amra
    Barut, Kenan
    Kasapcopur, Ozgur
    Evliyaoglu, Olcay
    [J]. CLINICAL RHEUMATOLOGY, 2024, 43 (01) : 399 - 406
  • [40] Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis
    Whittle, Samuel L.
    Glennon, Vanessa
    Johnston, Renea, V
    Avery, Jodie C.
    Bell, J. Simon
    Brennan, Sue E.
    Fong, Christopher
    Hissaria, Pravin
    Horgan, Ben
    O'Neill, Sean
    Pisaniello, Huai Leng
    Trevena, Lyndal
    Whittaker, Glen A.
    Wluka, Anita
    Buchbinder, Rachelle
    [J]. INTERNAL MEDICINE JOURNAL, 2022, 52 (10) : 1799 - 1805